<DOC>
	<DOCNO>NCT01085617</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . It yet know regimen combination chemotherapy give together without monoclonal antibody effective treat patient newly diagnose acute lymphoblastic leukemia . PURPOSE : This randomized phase III trial study standard chemotherapy see well work give together without rituximab , without nelarabine treat patient newly diagnose acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Standard Chemotherapy With Without Nelarabine Rituximab Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine addition monoclonal antibody ( none vs. rituximab ) improve event-free survival ( EFS ) patient newly diagnose precursor B-cell acute lymphoblastic leukemia ( ALL ) . - To determine addition nelarabine improve outcome patient T-cell ALL . Secondary - To determine tolerability pegaspargase induction therapy patient . - To compare anti-asparaginase antibody level patient B-lineage ALL . - To determine whether risk-adapted introduction unrelated donor hematopoietic stem cell transplantation ( HSCT ) ( myeloablative conditioning patient ≤ 40 year old non-myeloablative conditioning patient &gt; 40 year old ) result great EFS patient high risk relapse . - To compare efficacy two schedule ( standard v collapse ) palifermin prevent severe mucosal toxicity patient treat etoposide , total-body irradiation , HSCT-conditioning therapy . - To assess late effect treatment patient . - To identify describe adverse physical psychosocial consequence disease treatment . OUTLINE : This multicenter study . There 3 randomization different timepoints trial , patient undergoes least 1 2 randomization . - Part 1 standard induction therapy ( patients* , week 1-4 ) : Patients receive daunorubicin hydrochloride IV 20 minute vincristine sulfate IV 5-10 minute day 1 , 8 , 15 , 22 ; oral dexamethasone day day 1-5 , 8-11 , 15-18 ; pegaspargase IV 1-2 hour day 4 18 ; methotrexate intrathecally ( IT ) day 14 . NOTE : *Patients Philadelphia-positive ( Ph+ ) disease also receive oral imatinib mesylate day day 1-28 . - Randomized concurrent monoclonal antibody therapy ( patient precursor B-cell acute lymphoblastic leukemia [ ALL ] ) : Patients precursor B-cell ALL randomize 1 4 monoclonal antibody treatment arm ( give concurrently part 1 standard induction therapy ) : - Arm B1 : Patients receive monoclonal antibody therapy . - Arm B2 : Patients receive rituximab IV day 3 , 10 , 17 , 24 . - Part 2 standard induction therapy ( patients* , week 5-8 ) : Patients receive cyclophosphamide IV 30 minute day 1 15 ; cytarabine IV day 2-5 , 9-12 , 16-19 , 23-26 ; oral mercaptopurine day day 1-28 ; methotrexate IT day 1 , 8 , 15 , 22 . NOTE : *Patients Ph+ disease also receive oral imatinib mesylate day day 1-30 . - Randomized subsequent nelarabine therapy ( Patients T-cell ALL ) Patients T-cell ALL randomize 1 2 treatment arm , administer completion part 2 standard induction therapy . - Arm T1 : Patients receive therapy induction . - Arm T2 : Patients receive nelarabine IV 2 hour day 1 , 3 , 5 . Patients achieve complete remission ( CR ) part 2 standard induction therapy take study . - Intensification/central nervous system prophylaxis ( patient eligible transplant OR patient &gt; 40 year study entry eligible transplant ) * : Beginning recovery part 2 standard induction therapy , patient receive high-dose methotrexate IV day 1 15 pegaspargase IV 1-2 hour day 2 16 . NOTE : *Patients Philadelphia-positive ( Ph+ ) disease also receive oral imatinib mesylate day day 1-28 . Patients eligible allogeneic hematopoietic stem cell transplantation ( HSCT ) ( i.e. , patient HLA-compatible sibling donor high risk patient molecularly match donor ) undergo transplantation ; patient eligible HSCT undergo consolidation follow maintenance therapy . - Consolidation therapy* ( patient eligible transplantation ) : - Course 1 : Beginning completion intensification therapy , patient receive cytarabine IV high-dose etoposide IV 30 minute day 1-5 , pegaspargase IV 1-2 hour day 5 , methotrexate IT day 1 . Patients proceed course 2 begin 3 week start course 1 neutrophil recover . - Course 2 : Patients receive cytarabine IV high-dose etoposide IV 30 minute day 1-5 methotrexate IT day 1 . Patients proceed course 3 begin 3 week start course 2 neutrophil recover . - Course 3 ( delay intensification ) : Patients receive daunorubicin hydrochloride IV 20 minute vincristine sulfate IV 5-10 minute day 1 , 8 , 15 , 22 ; pegaspargase IV 1-2 hour day 4 ; oral dexamethasone day day 1-4 , 8-11 , 15-18 , 22-25 ; methotrexate IT day 2 17 ; cyclophosphamide IV day 29 ; cytarabine IV day 30-33 37-40 ; oral mercaptopurine day day 29-42 . Patients proceed course 4 neutrophil recover . - Course 4 : Patients receive cytarabine IV , high-dose etoposide IV , methotrexate IT course 2 . NOTE : *Patients Ph+ disease also receive oral imatinib mesylate day day 1-7 course 1 2 , day 2-42 course 3 , day 1-8 course 4 . - Maintenance therapy ( patient eligible transplantation ) : Patients receive vincristine sulfate IV every 3 month , oral prednisolone day day 1-5 every 3 month , oral mercaptopurine daily , methotrexate IV orally week , methotrexate IT every 3 month 2 year . - Transplant conditioning allogeneic HSCT : - Myeloablative-conditioning allogeneic HSCT ( patient ≤ 40 year old study entry ) : Patients undergo total-body irradiation day -7 -4 receive high-dose etoposide IV 4 hour day -3 high-dose cyclophosphamide IV 2 hour day -3 -2 . Patients undergo allogeneic HSCT day 0 . Patients stratify accord gender , donor ( sibling donor vs. match unrelated donor ) , cellular type ALL ( precursor B-lineage vs. T-lineage ) . Patients randomize receive 1 2 palifermin treatment arm . - Arm P1 ( standard dose ) : Patients receive palifermin IV day -3 2 . - Arm P2 ( collapse dose ) : Patients receive palifermin IV day -1 2 . - Non-myeloablative-conditioning allogeneic HSCT ( patient &gt; 40 year old study entry ) : Patients receive fludarabine phosphate IV 30-60 minute day -7 -3 melphalan IV 90 day day -1 . Recipients unrelated donor HSCT also receive alemtuzumab IV 2 hour day -2 -1 ; recipient sibling HSCT receive alemtuzumab IV 2 hour day -1 . Patients undergo allogeneic HSCT day 0 . Patients also receive post transplant methotrexate IT every 3 month 2 year . Patients undergo blood bone marrow sample collection periodically correlative study . After completion study treatment , patient follow annually . Peer Reviewed Funded Endorsed Cancer Research UK</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose , previously untreated acute lymphoblastic leukemia A prephase steroid treatment 57 day require start prior registration Philadelphia chromosomenegative positive patient eligible No blast transformation chronic myeloid leukemia No mature Bcell leukemia [ i.e. , Burkitt disease ( 8,14 ) ( q24 ; q32 ) ] variant cmyc translocation [ e.g. , ( 2 ; 8 ) ( p12 ; q24 ) , ( 8 ; 22 ) ( q24 ; q11 ) ] Patients undergo study transplantation must HLAcompatible sibling unrelated donor 8/8 molecular match A , B , C , DR ( DQ mismatch permit ) Patients meet ≥ 1 follow criterion consider highrisk : Over 40 year old WBC ≥ 30 x 10^9/L ( precursorB ) OR ≥ 100 x 10^9/L ( Tlineage ) Any 1 follow cytogenetic abnormality : ( 4 ; 11 ) ( q21 ; q23 ) /MLLAF4 Low hypodiploidy/near triploidy ( 3039 chromosomes/6078 chromosome ) Complex karyotype ( ≥ 5 chromosomal abnormality ) Philadelphia chromosome ( 9 ; 22 ) ( q34 ; q11 ) /BCRABL1 ( detect cytogenetic molecular method ) Highrisk minimalresidual disease completion part 2 standard induction therapy PATIENT CHARACTERISTICS : No known HIV infection Not pregnant nursing ( nurse 12 month completion study therapy ) Negative pregnancy test Fertile patient must use effective contraception 12 month completion study therapy PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>oral complication</keyword>
	<keyword>mucositis</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>B-cell adult acute lymphoblastic leukemia</keyword>
	<keyword>T-cell adult acute lymphoblastic leukemia</keyword>
	<keyword>Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia</keyword>
</DOC>